Anti-CD8 alpha antibody [EPR22483-288],Abcam,AB245118
What is this antibody validated in? Anti-CD8 alpha antibody [EPR22483-288] (ab245118) is a rabbit recombinant monoclonal antibody and is validated for use in Flow Cytometry (Flow Cyt), Immunoprecipitation (IP), Immunohistochemistry (IHC-P), Multiplex IHC (mIHC) in Human samples. Trial sizes available! Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 10µl. Discover our selection of trial-size antibodies. Other related products We have a range of other formats of antibody clone [EPR22483-288] also available for your convenience: ab245118, Carrier free - ab245830 Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .
Host
Rabbit
Reactivity
Human
Application
IP, Flow Cyt, IHC-P, mIHC
Platform ID
BAB380684064
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data The protein expressed by the gene CD8A is an integral membrane glycoprotein crucial for immune responses, operating mainly in T-cells as a coreceptor for MHC class I molecule : peptide complexes. These peptides originate from cytosolic proteins, unlike class II peptides, which are from extracellular proteins. CD8A interacts with the T-cell receptor (TCR) and MHC class I proteins on antigen-presenting cells, recruiting the Src kinase LCK to the TCR-CD3 complex. LCK phosphorylates substrates, triggering signaling pathways that lead to the production of lymphokines, enhanced motility, adhesion, and activation of cytotoxic T-lymphocytes (CTLs), thereby aiding in the recognition and elimination of infected or tumor cells. Additionally, in natural killer (NK) cells, CD8A homodimers on the cell surface provide a survival mechanism for conjugating with and lysing multiple target cells. CD8A homodimers also facilitate the survival and differentiation of activated lymphocytes into memory CD8 T-cells. This supplementary information is collated from multiple sources and compiled automatically. See full target information CD8A
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
- Products>Trial Size Antibodies
Please provide the required information below so that we can quickly source your products.